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ABSTRACT:
The crystal structure of LRH-1 ligand binding domain bound to our previously reported agonist 3-(E-oct-4-en-4-yl)-1-
phenylamino-2-phenyl-cis-bicyclo[3.3.0]oct-2-ene 5 is described. Two new classes of agonists in which the bridgehead anilino
group from our ﬁrst series was replaced with an alkoxy or 1-ethenyl group were designed, synthesized, and tested for activity in a
peptide recruitment assay. Both new classes gave very active compounds, particularly against SF-1. Structure-activity studies led to
excellent dual-LRH-1/SF-1 agonists (e.g., RJW100) as well as compounds selective for LRH-1 (RJW101) and SF-1 (RJW102 and
RJW103). The series based on 1-ethenyl substitution was acid stable, overcoming a signiﬁcant drawback of our original bridgehead
anilino-substituted series. Initial studies on the regulation of gene expression in human cell lines showed excellent, reproducible
activity at endogenous target genes.
’ INTRODUCTION
The nuclear receptor (NR) superfamily in mammals com-
prises a highly conserved group of 49 receptors that act as
transcription factors to regulate development, homeostatic phy-
siology, and cellular metabolism.1 Nearly half of all NRs are
ligand regulated, responding to dietary or endocrine signals such
as steroid hormones, retinoids, vitamin D, fatty acids, and thyroid
hormone. As such, NRs are attractive targets for drug discovery,2
and indeed, 13% of current FDA-approved drugs regulate NRs.3
NRs without assigned natural ligands are referred to as orphan
NRs.4 On the basis of structural analyses of nearly all NR
subfamilies, it is predicted that most orphan receptors might
accommodate ligands, thus providing novel targets for pharma-
ceuticals. Finding natural or synthetic regulatory ligands for these
orphan receptors is key to understanding their role in physiology,5
a process termed “reverse endocrinology”.6 Attempts to “adopt”
(or deorphanize) orphan NRs have been successful for NR1H4
(farnesoid X receptor, FXR)7 and peroxisome proliferator-
activated receptor family (PPARs, NR1Cs)8 and have led to
useful therapeutics.
Here, we have undertaken an eﬀort to identify synthetic
ligands for subfamily V members, including steroidogenic fac-
tor-1 (SF-1, NR5A1),9 and its close homologue, liver receptor
homologue-1 (LRH-1, NR5A2).10 Both receptors are known to
play important roles during embryonic development and in adult
physiology.
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SF-1 (NR5A1) is a critical factor in vertebrate endocrine organ
development, including male sexual diﬀerentiation, and is an
important regulator of steroidogenic enzymes.11 Numerous
genetic mutations in the DNA binding domain (DBD) and
ligand binding domain (LBD) of SF-1 correlate with abnormal
testis development12 and premature ovarian failure.13 By con-
trast, ampliﬁcation of SF-1 is associated with adrenocortical tumors,
with inverse agonists reported to inhibit proliferation of primary
cultured tumor cells.14 SF-1 has also been implicated in the
development of endometriosis and endometrial cancers.15
Finally, rodent models suggest that SF-1 expressed in the hypotha-
lamus inﬂuences anxiety, energy homeostasis, and appetite.16
LRH-1 plays a critical role in embryonic development of the
endoderm17 and is highly expressed in the intestine, liver,
exocrine pancreas, and ovary.18 LRH-1 regulates crucial enzymes
in hepatic bile acid biosynthesis19 and cholesterol homeostasis10
and is a key controller in the hepatic acute phase response.20
Thus, this receptor may be a target for the treatment of cardio-
vascular disease21 and cholinostatic liver disease.22 LRH-1 and
SF-1 both regulate aromatase expression,23 and LRH-1 is expressed
in several human breast cancer cell lines, suggesting that antago-
nists in combination with traditional aromatase inhibitors might
be eﬀective in reducing local concentrations of estrogen in human
breast carcinomas.24 Finally, LRH-1 is expressed in human intest-
inal crypt cells where it controls cell proliferation and diﬀeren-
tiation.25 Its expression26 and potential role in gastric cancer27
suggest that LRH-1 can inﬂuence tumor formation by accelerat-
ing the cell cycle and promoting inﬂammation.28
Both SF-1 and LRH-1 have emerged as potential stem cell
factors because both can regulate expression of Oct-4, which is
one of the four factors found to induce pluripotency of mouse
embryonic ﬁbroblasts.17,29 Moreover, these two NRs can
completely replace Oct-4 to reprogram murine somatic cells to
induce pluripotent cells30a and are also potent inducers in the
transition from an epiblast stem cell to ground state pluripotency
(iPS).30b As such, identifying eﬀective agonists to either SF-1 or
LRH-1 might help in achieving a pharmaceutical approach in
generating or maintaining pluripotent human stem cells.
LRH-1 and SF-1 bind to DNA as monomers and show
constitutive activity when expressed in a variety of cell types.9,10
Receptor activity can be regulated by post-translational modiﬁ-
cations including phosphorylation31 and sumoylation32 or through
interaction with the atypical orphan receptors that lack a DBD,
including small/short heterodimer partner (SHP, NR0B1)33 and
DAX-1, Dosage-sensitive sex reversal, adrenal hypoplasia critical
region, on chromosome X, gene 1) (NR0B2).34
X-ray crystallography coupled with mass spectroscopy
revealed the presence of Escherichia coli-derived phospholipids,
phosphatidylglycerides (1; Figure 1) and phosphatidylethanol-
amines (2a) in the ligand binding pockets of human LRH-1 and
SF-1.35 The majority of phospholipids bound to either SF-1 or
human LRH-1 LBD were identiﬁed as having C16 or 18 acyl
groups with some showing a cis-alkene in the Δ9 position.
Whether these phospholipids merely serve as structural ligands
or serve a regulatory role remains to be established. Support for
phospholipids as regulatory ligands includes increased coactiva-
tor peptide recruitment on binding of phospholipids to SF-135c
and a correlation between binding of phospholipid and LRH-1-
induced activation of gene expression.35d The exchange of
bacterially derived phosphatidyl glyceride (1) with phospholi-
pids such as 335b and phosphatidycholine (2b) has been demons-
trated.36 In the latter case, the exchange had little eﬀect on
binding of coactivator peptides.36 Recently, Moore has claimed
in a patent that diundecanoyl (2b, R1 = R2 = nC9H19) and
dilauroyl (2b, R1 = R2 = nC11H23) phosphatidylcholine (PC) act
as agonists of the LRH-1 receptor and that administration of
these lipids to diabeticmice reduces blood glucose levels.37 Other
correlative data include the ﬁnding that SF-1 activation by a
tamoxifen analogue increases cellular levels of phosphatidylino-
sitol (3,4,5) triphosphate (3).15c Finally sphingosine (4) is
reported to bind SF-1 and suppress expression of the SF-1 target
gene CYP17a1.38 Derivatives of (4) such as sphingosylpho-
sphorylcholine and N-Acyl-4 (ceramides) may also be natural
ligands.
We reported the ﬁrst synthetic small molecule agonist for
LRH-1 and SF-1, GSK8470 (5), and a structure-activity rela-
tionship (SAR) study on the series 6 leading to the more active
analogue 7 (Figure 2).39 Another small molecule known to activate
both SF-1 and LRH-1 is the herbicide atrazine,40 but the precise
mechanism leading to this increased receptor activity has yet to
be deﬁned.
Recently, p-heptyloxyphenol (8) was reported as a potent
(IC50 = 7.3 μM) inverse agonist for SF-1 but with no activity
against LRH-1.41 Expression of several reported SF-1 target genes
was suppressed by 8 in cell-based assays. However, although 8
was reported to inhibit proliferation of adrenocortial carcinoma
cell line H295R, it had the same eﬀect with an SF-1 negative cell
line (SW-13).14 Several isoquinoline-based inverse agonists of
SF-1 were discovered through high-throughput screening and
Figure 1. Natural ligands for LRH-1 or SF-1.
Figure 2. Synthetic compounds reported to modulate SF-1 or LRH-1
activity.
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further SAR studies, of which 9 was most active (IC50 =
200 nM).41,42 At high levels (10 μM), 9 modestly suppressed
doxycycline (DOX) induced proliferation of H295R cell line
with little eﬀect on the SF-1 negative SW-13 cell line. Closely
related isoquinolines aﬀected both cell lines in a similar way,
suggesting a non-SF-1 mechanism. The SAR for these series
seems complex; for example, replacing the methoxy group in 9
with ethoxy gave a compound highly active against a range of
other receptors and exhibiting strong cell toxicity, suggesting
transactivation assay artifacts (promiscuous inhibition of the
reporter system).
Although 5 and related compounds 6 have proven to be
excellent biological probes for LRH-1 and SF-1, they have a
number of limitations.Most important is that they are unstable to
acid, making handling diﬃcult and raising doubts about stability
during biological application. The series also shows little discri-
mination between LRH-1 and SF-1. The aim of this work was
thus ﬁrst to develop new series of compounds that were more
stable and easily handled than series 6, but with at least compar-
able binding and eﬃcacy, and second to ﬁnd compounds that
were selective for LRH-1 and/or SF-1.
’COCRYSTAL STRUCTURE OF 5 WITH hLRH-1
As a basis for the design of improved analogues of 5, we solved
the cocrystal structure of compound 5 bound to the human LRH-
1 LBD (Figures 3 and 4). Although racemic 5 was used, the
1S,5R-bicyclo[3.3.0]oct-2-ene enantiomer cocrystallized with
LRH-1 LDB. Compound 5 occupied the same binding pocket
volume as the terminal 12 carbon atoms in both acyl chains of a
phospholipid bound in LRH-1.35b This smaller size permitted
LRH-1 to contract, narrowing the gap between the N-terminal
half of helix 3 (residues 338-350, yellow in the PL-bound
structure) and the β-turn/helix 6 region (residues 408-427, orange
in the PL-bound structure) where the phospholipid headgroup is
situated in the PL þ LRH-1 structure, and completely enclose
the ligand within the binding pocket. Making no polar interac-
tions with the protein, 5 was a compact, hydrophobic mass
complementing the inner surface of the binding pocket. There
was π stacking between the His390 and the aniline of 5 with a
centroid-centroid distance of 3.8 Å and a deviation from
coplanarity of around 10.
Figure 3. CR trace from the phospholipid35b (magenta, orange, and
yellow) and 5 (white) bound conformations of LRH-1 were super-
imposed for comparison. The pocket contracts around the smaller 5,
with the biggest shifts occurring for residues 338-350 in helix 3 (yellow)
and residues 408-427 in the β-turn and helix 6 (orange), where the
phospholipid headgroup protrudes.
Figure 4. Compound 5 is shown in the LRH-1 ligand binding pocket.
Contacting residues are indicated, along with the His390-aniline
distance. The surface of the pocket is shown, colored by the nearest
atom type. The region of the pocket adjacent to helix 5 and the β-turn
contain polar residues and several trapped water molecules.
Figure 5. Two-dimensional compound interaction diagram depicting
adjacent residues and theπ stacking interaction withHis390. The crystal
structure is available from the RCSB with access code 3PLZ and is
further described in the Experimental Section.
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The structure suggested some chemical strategies for improv-
ing compound properties. The acid-labile aniline nitrogen made
no polar interactions with the protein, suggesting that another
more stable linker might be tolerated. We thus designed com-
pounds with oxygen- and carbon-based linkages from the sub-
stituted bridgehead carbon. Additionally, His390, Arg393, and
Gln432 were within 5 Å of the compound. Polar moieties could
be incorporated to interact with these residues, which might
both improve binding and increase hydrophilicity of the ligand
(Figure 5).
’CHEMISTRY
Alkoxy-Substituted Series. Racemic tertiary alcohol 11 was
synthesized as previously reported39 from hept-6-en-1-yn-
1-ylbenzene via Pauson-Khand cyclization to give the cyclo-
pentenone 10 and cerium trichloride-assisted 1,2-addition of
hexylmagnesium bromide (Scheme 1). Exposure of 11 to various
alcohols in the presence of catalytic amounts of camphorsulphonic
acid gave a series of racemic analogues 12 of 7 in which an alkoxy
group replaced the aniline substituent. Yields for the last step
were generally good (Table 1), the exception being when the
alcohol carried an R-branch. The products 12 were unstable to
silica, so were purified by column chromatography on basic grade
III alumina.
“All Carbon” Series. A previously reported43 tandem reaction
sequence on zirconocene was used to construct “all carbon”
analogues 18 of 7. Thus, intramolecular cocyclization of 1,6-enyne
13 gave the zirconacyclopentenes 14 (Scheme 2). The addition
of a 1,1-dihaloalkyl compound followed by lithium diisopropy-
lamide (LDA) or lithium 2,2,6,6-tetramethylpiperidide (LiTMP)
generated a carbenoid R2X2CLi in situ, which when inserted into
Scheme 1. Preparation of Bridgehead-Alkoxy Seriesa
aReagents and conditions: (a) Co2(CO)8, DMSO (10 equiv), THF,
reﬂux, 5 h, 80%. (b) nC6H13MgBr, CeCl3,-10 C to room temperature,
1 h, 90%. (c) ROH (10 equiv), camphorsulfonic acid (0.1 equiv),
20 C, 3.5 h.
Table 1. Synthesis of 1-Alkoxy-3-hexyl-2-phenyl-cis-bicyclo-
[3.3.0]oct-2-enes 12a-j
compound R yield (%)a
12a Me 75
12b Et 69
12c nPr 71
12d iPr 7
12e nBu 68
12f CH2CH(Me)(Et) 64
12g nPent 62
12h nHex 65
12i cHex 12
12j CH2Ph 69
a Isolated yield from 11.
Scheme 2. Preparation of Bridgehead 1-Alken-2-yl-Substi-
tuted Systemsa
aReagents and conditions: (a) (i) Cp2ZrBu2, THF, -78 C, 0.5 h; (ii)
room temperature, 2 h. (b) R2CHX2 (X = Br for R
2 = nHex, nBu, nOct;
X = Cl for R2 = H, SiMe2Ph), LDA or LiTMP, -78 C, 15 min. (c)
R3CtCLi (3 equiv),-78 to-60 C over 0.5 h. (d) MeOH, NaHCO3,
room temperature, 12-16 h.
Table 2. Synthesis of 1-(2-Alkenyl)-bicyclo[3.3.0]oct-2-enes 18
R1 R2 R3 yield (%)a
18a Ph nHex Ph 86
18b Ph nHex 3-MeOPh 78
18c Ph nHex 4-MeOPh 72
18d Ph nHex 4-MePh 62
18e Ph nHex 4-EtPh 70
18f Ph nHex 4-nBuPh 78
18g Ph nHex 4-tBuPh 51
18h Ph nHex 4-PhPh 60
18i Ph nHex nPr 54
18j Ph nHex nBu 75
18k Ph nHex nHex 65
18l Ph nHex nOct 56
18m 3-MeOPh nHex Ph 75
18n 4-EtPh nHex Ph 70
18o nPr nHex Ph 82
18p nBu nHex Ph 88
18q nHex nHex Ph 86
18r cHex nHex Ph 80
18s (CH2)3OH nHex Ph 61
18t Ph H Ph 58
18u Ph nBu Ph 71
18v Ph nOct Ph 73
18w Ph SiMe2Ph Ph 45
a Isolated yield of >95% pure material.
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the alkyl-zirconium bond of 14 afforded the ring-expanded
zirconacyclohexene 15. The addition of a lithiated alkyne in-
duced a ring-closing rearrangement to the bicyclo[3.3.0]oct-1-
ene 16, which rearranged further to the zirconocene alkylidene-
ate complex 17, incorporating a second alkyne moiety. Aqueous
workup gave the racemic 1-(2-alkenyl)-bicyclo[3.3.0]oct-2-enes
18a-w in generally excellent yield (Table 2) for a single-pot,
three-component coupling. The yields were poorer when di-
chloromethane was the carbenoid precursor due to bis- and tris-
insertion of the derived carbenoid into the zirconacycle.
The tandem reaction sequence also worked for the forma-
tion of the racemic bicyclo[4.3.0]non-8-ene 19 and pyrroli-
dine fused systems 20a,b (Scheme 3). The low yield for
compound 19 reﬂected a diﬃcult separation from by-products
—the yield estimated from the partially puriﬁed product
was 46%.44
Compounds carrying oxygen substitution on the saturated
cyclopentane ring were required. The synthesis of the 6-oxyge-
nated compounds is shown in Scheme 4.
Using ethanol and in situ-generated Me3SiI, acrolein was
converted into 1,1-diethoxy-3-iodopropane,45 which after rapid
puriﬁcation by chromatography on basic alumina (grade III) was
reacted with lithium phenylacetylide to give (5,5-diethoxypent-1-
yn-1-yl)benzene. Hydrolysis of the acetal to give an aldehyde was
followed by reaction with vinylmagnesium bromide to aﬀord the
alcohol 21. Protection of the hydroxyl group with tBuMe2SiOTf
gave the desired cyclization precursor 22, which underwent the
zirconocene-induced cocyclization, carbenoid insertion, and phenyl
acetylide addition to give a 1.6:1 mixture of the exo and endo
isomers 23 after protonolysis. Tetrabutylammonium ﬂuoride
(TBAF) cleavage of the silyl group furnished the desired racemic
bicyclic alcohols 24. The exo and endo isomers were separated by
careful chromatography on silica, with the endo isomer eluting
ﬁrst. The relative stereochemistries of the exo and endo isomers
were clear from coupling patterns to the proton adjacent to the
hydroxyl group. In the endo isomer, it appears as a ddd, J = 9.1,
8.5, 5.5 Hz, and in the exo isomer, it appears as a broad singlet, the
patterns being in accordwith expectations frommolecularmodeling
and the Karplus relationship of couplings to dihedral angles.46
The separated diastereoisomers of 24 were acylated to aﬀord 25-
endo and 25-exo. A crystal structure of 25-endo conﬁrmed the
stereochemical assignment.47 The 7-oxygenated series was syn-
thesized as shown in Scheme 5.
A single-pot ring-closure/ring-opening procedure was used to
convert pent-4-ene-1,2-diol48 into alcohol 26.49 Thus, selective
tosylation of the primary alcohol was followed by in situ ring closure
to an epoxide and ring-opening with lithium phenylacetylide to
aﬀord the alcohol 26.50 The overall yield was poor despite
considerable optimization. tBuMe2Si (TBDMS) protection of
26 gave 27, which underwent zirconocene-mediated cocycliza-
tion, dibromocarbenoid insertion, and phenylacetylide-driven
Scheme 3. Preparation of Cyclohexyl- and Pyrrolidine-Fused
Systemsa
aReagents and conditions: (a) (i) Cp2ZrBu2, THF, -78 C, 0.5 h; (ii)
room temperature, 2 h; (iii) nHexCHBr2, LDA, -78 C, 15 min; (iv)
PhCtCLi (3 equiv),-78 to-60 C over 0.5 h; (v) MeOH, NaHCO3,
room temperature, 12-16 h.
Scheme 4. Preparation of 6-Oxygenated Systemsa
aReagents and conditions: (a) (i) NaI, Me3SiCl, MeCN; (ii) EtOH,
0 C to room temperature, 2 h. (b) PhCtCLi (1.5 equiv), THF, HMPA
(1.5 equiv), -78 C, 1 h then room temperature, 14 h. (c) THF:H2O
(4:1), HCl (2M), room temperature, 3 h. (d) (i) CH2CHMgBr,-78 to
-65 C, 1 h; (ii) NH4Cl(aq). (e) tBuMe2SiOTf, imidazole, DMAP,
THF, room temperature, 18 h. (f) (i) Cp2ZrBu2, THF -78 C, 0.5 h
then 3 h at room temperature; (ii)-78 C, nHexCHBr2, LDA, 15 min;
(iii) PhCtCLi (3.0 equiv), -78 C to -60 C over 45 min; (iv)
MeOH/NaHCO3(aq), room temperature, 5 h. (g) TBAF (5 equiv),
THF, room temperature, 20 h. (h) Pyridine, Ac2O (73 equiv), DMAP
(0.58 equiv), 13 h.
Scheme 5. Preparation of 7-Oxygenated Systemsa
aReagents and conditions: (a) (i) NaH, THF, -10 C; (ii) N-tosyl
imidazole, -10 C, 1 h. (b) PhCtCLi (2 equiv), THF, HMPA
(2 equiv), -10 to 0 C over 1 h then room temperature, 40 h; (iii)
saturated NaHCO3(aq). (c) Me2tBuSiOTf, imidazole, DMAP, THF,
room temperature, 15 h. (d) (i) Cp2ZrBu2, -78 C, 0.5 h then 3 h at
room temperature; (ii) nHexCHBr2, LDA, -78 C; (iii) PhCtCLi
(3 equiv),-78 C to-60 C over 45 min; (iv) MeOH/NaHCO3(aq),
room temperature, 5 h. (e) TBAF (2 equiv), THF, room temperature,
20 h. (f) Pyridine, Ac2O (75 equiv), DMAP (0.58 equiv), room
temperature, 17 h.
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zirconate rearrangement to give a 1:1 mixture of the exo and
endo isomers 28. After TBAF cleavage of the silyl group, the
racemic exo and endo isomers of 29 were separated by careful
chromatography, with the endo isomer eluting ﬁrst. Acylation
of the separated diastereoisomers furnished 30-exo and 30-
endo.
The relative stereochemistries of 29-exo and 29-endo (and
hence 30-exo and 30-endo) were established by nuclear magnetic
resonance (NMR) studies combined with molecular modeling
(Table 3) using the MMFF94 force ﬁeld as implemented in
Spartan 06 (Wavefunction Inc.).51 The proton next to the
hydroxyl group in one isomer appeared as a tt, J = 8.5, 5.9 Hz
(due to couplings of 8.5, 8.3, 6.3, and 5.5 Hz), consistent with 29-
exo or the equatorial conformer of 29-endo (29-endo eq. conf.),
but as a quintet (J = 5.5 Hz) in the other diastereoisomer, not
consistent with any minimum energy structure. Molecular mod-
eling showed that 29-exo had a well-deﬁned minimum energy
conformer, but for 29-endo, the “equatorial” and “axial” hydroxy
conformers (29-endo eq. and 29-endo ax.) were <1 kJ/mol
diﬀerent in energy. The expected coupling patterns for each
conformer of 29-endo were calculated using the Altona modi-
ﬁcation46b of the Karplus relationship46a between dihedral angle
and 3J as implemented in the Mspin program52 from Mestrec.
The average showed a good correlation to the observed coupling
constants (Table 3).
Stability Tests.Compounds 18a, 24-exo, 24-endo, 28-exo, and
28-endo were stable after being kept in CDCl3 at room tempera-
ture in the presence of daylight for 2 weeks or being exposed to
1.0 equiv of (þ)-camphorsulfonic acid in CDCl3 at room
temperature for 1 week.
’RESULTS AND DISCUSSION
The compounds 12a-j, 18a-w, 19, 20a,b, 24, 25, 29, and 30
were screened for activity against both hLRH-1 and hSF-1 using
ﬂuorescence resonance energy transfer (FRET)-based peptide
recruitment assay. Puriﬁed bacterial-expressed LBDs35b of hu-
man LRH-1 or human SF-1 were labeled with biotin and incu-
bated with APC-labeled streptavidin (Molecular Probes). Pep-
tides derived fromTIF-2 amino acids 737-757 (B-QEPVSPKK-
KENALLRYLLDKDDTKD-CONH2) for LRH-1 or from DAX-1
amino acids 1-23 (B-MAGENHQWQGSILYNMLMSAKQT-
CONH2) for SF-1 were labeled with biotin and incubated with
europium-labeled streptavidin (Perkin-Elmer, Wallac). The labeled
receptor and peptide were incubated in the presence of various
concentrations of test compound, and the associated complexes
were quantiﬁed by time-resolved ﬂuorescence energy transfer
(TR-FRET). The pEC50 values of the test compounds, which
serve as a measure of the binding aﬃnity for the receptor, were
estimated from a plot using the ratio of ﬂuorescence values
collected at 671 nm to ﬂuorescence values collected 618 nm
versus concentration of test compound added. Typically, 11
points over the concentration range 1 nm to 10 μM was used to
construct each dose-response curve, and the pEC50 was calcu-
lated using ActivityBase 5.4 software. Six and three repeats
were carried out for LRH-1 and SF-1, respectively. Test
compounds that increased the aﬃnity of the receptors for the
peptide yielded an increase in ﬂuorescent signal. The dose-
response curves were sigmoidal with a clear plateau at high
concentrations of test compound, the level of which we report as
the relative eﬃcacy (RE) of peptide recruitment. In the absence
of a known standard, the value of RE was normalized to 24-exo
for both LRH-1 and SF-1. The average standard deviations of the
pEC50 values for LRH-1 and SF-1 were 0.07 and 0.08, respec-
tively, hence, the retention of the ﬁrst decimal place. The average
standard deviations of the RE values for LRH-1 and SF-1 were
0.034 and 0.025, respectively, hence, the retention of the second
decimal place in the reported values but with an approximately
(0.03 95% conﬁdence limit.
Table 3. Correlation between Predicted and Observed Coupling Constants for 29
between H7-H8b H7-H8a H7-H6b H7-H6a H6b-H5 H6a-H5
29-exo
dihedral angle () 164 47 154 37 14 104
calcd 3J (Hz) 10.2 6.1 8.9 7.6 9.7 1.9
observed 3J (Hz) 8.5 5.5 8.3 6.3 10 3.6
29-endo ax. conf.
dihedral angle () 38 80 33 87 18 101
calcd 3J (Hz) 5 1.3 5.9 1.3 9.4 1.6
29-endo eq. conf.
dihedral angle () 44 159 46 165 35 155
calcd 3J (Hz) 6.6 9.5 6.3 10.4 7.3 10.5
average calcd 29-endo eq. and -ax. conf. 3J (Hz) 5.8 5.4 6.1 5.9 8.4 6.1
observed 3J (Hz) 6.2 4.6 5.6 5 9.5 6
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The screening data are presented in several tables. Table 4
shows the alkoxy-substituted series 12a-j, and Tables 5-7 show
the series 18 compounds with emphasis on variation at the 1-, 2-,
and 3-positions of the bicyclo[3.3.0]oct-2-ene skeleton, respec-
tively. Table 8 contains the alternative core structures of 19 and
20. Finally, Table 9 provides results from compounds 24, 25, 29,
and 30 with oxygen substitution on the cyclopentane ring.
We were pleased to ﬁnd that many of the alkoxy-substituted
analogues were active against both LRH-1 and SF-1, showing
that the nitrogen in the aniline series 6 (exempliﬁed by 5 and 7)
was not necessary. All of the compounds (except 12j) bound less
strongly to LRH-1 and induced less recruitment of peptide than
the aniline series, suggesting that an aromatic group is preferred
by LRH-1 in this region. Unfortunately, it was not possible to
make the OPh-substituted system as it was highly unstable, both
because phenoxide is a much better leaving group than alkoxides
but also because phenol will act as an acid catalyst for decom-
position. The compounds showed good selectivity for SF-1, with
binding approaching and eﬃcacy exceeding that of our currently
most used biological tool 5. For both LRH-1 and SF-1, there is a
clear SAR relating to the size of the R group with both small
groups (Me) and large groups giving inactive compounds. The
cutoﬀ for large chains is sharp, indicating a deﬁned pocket being
Table 4. LRH-1 and SF-1 Binding and Activation of Alkoxy-
Substituted Series 12
pEC50 (RE)
compound R LRH-1 SF-1
5 6.2 (0.89) 6.8 (0.36)
7 7.5 (0.38) 7.4 (0.70)
12a Me ia ia
12b Et 5.6 (0.17) 6.3 (0.55)
12c nPr 5.6 (0.21) 6.7 (0.67)
12d iPr 5.5 (0.19) 6.4 (0.49)
12e nBu 5.3 (0.39) 6.6 (0.62)
12f CH2CH(Me)(Et) 5.6 (0.18) 6.7 (0.56)
12g nPent ia 6.4 (0.43)
12h nHex ia ia
12i cHex 6.1 (0.16) 7.1 (0.66)
12j CH2Ph 7.0 (0.13) ia
Table 5. Variation of Bridgehead Substituent in Series 18
Compounds
pEC50 (RE)
compound R LRH-1 SF-1
18a Ph 6.6 (0.24) 7.2 (0.78)
18b 3-MeOPh 6.5 (0.25) 7.2 (0.28)
18c 4-MeOPh ia ia
18d 4-MePh 5.7 (0.25) 6.8 (0.28)
18e 4-EtPh ia ia
18f 4-nBuPh 6.0 (0.14) ia
18g 4-tBuPh ia ia
18h 4-PhPh ia ia
18i nPr 5.5 (0.23) 6.8 (0.66)
18j (RJW102) nBu 5.6 (0.19) 6.7 (0.76)
18k nHex ia ia
18l nOct ia ia
Table 6. Variation of 2-Substituent in Series 18 Compounds
pEC50 (RE)
compound R LRH-1 SF-1
18a Ph 6.6 (0.24) 7.2 (0.78)
18m 3-MeOPh 6.6 (0.13) 6.9 (0.42)
18n 4-EtPh ia ia
18o nPr ia 6.4 (0.56)
18p nBu ia 6.6 (0.59)
18q nHex ia ia
18r cHex 5.9 (0.15) 6.7 (0.59)
18s (RJW101) (CH2)3OH 6.1 (0.38) ia
Table 7. Variation of 3-Substituent in Series 18 Compounds
pEC50 (RE)
compound R LRH-1 SF-1
18a nHex 6.6 (0.24) 7.2 (0.78)
18t H ia ia
18u nBu 6.7 (0.54) 7.4 (0.86)
18v nOct 5.8 (0.15) 6.8 (0.67)
18w SiMe2Ph 6.8 (0.53) 7.2 (0.33)
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ﬁlled. For LRH-1, this is above four carbons long [cyclohexyl,
CH2CH(Me)(Et), and n-butyl all ﬁt, while n-pentyl does not].
For SF-1, the pocket appears slightly larger with n-pentyl, but
not n-hexyl ﬁtting. These results are comparable to those
observed with aniline series 6, compounds where 3- or 4-sub-
stitution on the NAr ring gave reduced binding or inactive
compounds.39 An interesting exception was the benzyloxy deriv-
ative 12j, which displayed excellent binding to LRH-1, although
poor eﬃcacy, but was inactive against SF-1. It seems likely that π
stacking with His-390 as described above for compound 5 results
in the strong binding. Although the alkoxy-substituted series
provided candidates for some of our key aims including the SF-1
and LRH-1 selective compounds 12g and 12j, respectively, these
compounds proved as acid sensitive as the aniline series, as
evidenced by their decomposition on attempted chromatogra-
phy on silica or when stored in glassware that had not been
washed with base.
The acid instability of series 12 prompted us to test compound
18awith a similar cis-bicyclo[3.3.0]oct-2-ene structure but which
lacked the acid-sensitive bridgehead leaving group, and it was
found to exhibit good binding and activation of both LRH-1 and
SF-1 (Table 5).
Variation of the lithiated alkyne used in the multicomponent
synthesis of 18 allowed variation of the bridgehead substituent
(Table 5). As with the series 12 compounds, we observe a strict
cutoﬀ in the size of group R, which can be accommodated. Even
addition of a para-methyl group to the preferred phenyl sub-
stituent decreased binding (18d), and anything larger (18e-h)
gave inactive compounds. The potent binding, although poor
eﬃcacy, of 18f with LRH-1 is an anomaly and perhaps indicates
an approach to developing reverse agonists of LRH-1. Interest-
ingly, a 3-MeO group was well tolerated perhaps indicating some
stabilization via dipolar interactions or weak H-bonding, whereas
a 4-OMe substitution gave an inactive compound (18c). When R
is an alkyl group (18i-l), LRH-1 binds only the shortest tried
(R = nPr, nBu 18i,j) and then with low pEC50 and eﬃcacy. The
comparison of 18j (R = nBu) with the similarly sized but much
more active 18a (R = Ph) indicates a strong preference for an aryl
group correlating with aromatic stacking with His390 noted in
the crystal structure of LRH-1 and 5 above. SF-1 bound the R =
nBu compound 18j strongly and with good eﬃcacy, conﬁrming
the larger pocket noted in the SAR of series 12 and providing a
good SF-1 selective analogue in the FRET assay. The longer
chain compounds 18k (R = n-hexyl) and 18i (R = n-octyl) were
inactive.
Changing the 1,7-enyne starting material allowed the SAR due
to variation of the substituent on position 2 of the bicyclo-
[3.3.0]oct-2-ene to be probed (Table 6). The tight constraints
and preference for aryl groups of the LRH-1 binding site were
again apparent. Although a 3-methoxyphenyl group (18m) was
tolerated, 4-ethylphenyl (18n) was not, and surprisingly, neither
of R = nPr or nBu (18o,p), both similar sizes to a phenyl group,
gave active compounds. R = cyclohexyl (18r) gave modest
binding and poor eﬃcacy but conﬁrms the preference for cyclohexyl
over n-alkyl observed in the alkoxy series above (Table 4). SF-1
proved much more accommodating, consistent with the larger
ligand binding pocket, although compounds with 4-ethylphenyl
(18n) or n-hexyl (18q) substituents were not active. nPr-, nBu-,
and c-hexyl-substituted compounds (18o,p,r) all gave similar
binding and eﬃcacy with SF-1 but distinctly poorer than com-
pound 18a (R = Ph). Remarkably, the 3-hydroxypropyl sub-
stituent in 18s gave good binding and activation of LRH-1 but
was inactive against SF-1, providing the only example of a highly
LRH-1 selective compound. The hydroxyl group may be in a
position to form a hydrogen bond with a backbone carbonyl in
the N-terminal region of helix 3 of LRH-1. The inactivity of 18s
indicates this to be a very nonpolar area in SF-1.
Using alternative dihalocarbenoids in the formation of 18
allowed the biological eﬀect of variation in the 3-substituent
(Table 7) to be studied. The case R = H gave an inactive com-
pound against both receptors, indicating that the ligand binding
pocket needs to ﬁlled for binding and/or activity. Shortening the
n-hexyl (8a) substituent to n-butyl (18u) gave a substantial
increase in eﬃcacy for LRH-1without aﬀecting SF-1 in the FRET
assay. The bulky SiMe2Ph substituent gave a substantial increase
in eﬃcacy for LRH-1 and a modest decrease in both binding and
eﬃcacy for SF-1 (compare 18w with 18a). An n-octyl chain gave
some reduction in binding and eﬃcacy, particularly for LRH-1.
Table 9. Eﬀect of Oxygen Substitution on the Cyclopentane
Ring
pEC50 (RE)
compound LRH-1 SF-1
18a 6.6 (0.24) 7.2 (0.78)
24-exo (RJW100) 6.6 (1.00) 7.5 (1.00)
24-endo 6.4 (0.67) 7.2 (0.77)
25-exo 6.4 (0.18) 6.4 (0.25)
25-endo 6.6 (0.18) 7.1 (0.24)
29-exo 6.0 (0.53) 6.6 (0.49)
29-endo 5.8 (0.33) 6.5 (0.95)
30-exo ia ia
30-endo 6.3 (0.13) 6.7 (0.34)
Table 8. Eﬀect of Variations in Skeleton on Biological
Activity
pEC50 (RE)
compound LRH-1 SF-1
18a 6.6 (0.24) 7.2 (0.78)
19 6.6 (0.23) 7.2 (0.42)
20a (RJW103) 5.9 (0.20) 6.5 (0.49)
20b 6.5 (0.13) ia
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We also looked at variation in the core skeleton (Table 8). The
only eﬀect of changing the fused saturated ring from cyclopen-
tane (in 18a) to cyclohexane (in 19) was reduced eﬃcacy against
SF-1. The pyrrolidine-fused systems 20a,b oﬀered the potential
of improved solubility. The N-methyl compound 20a was active
against both receptors, although with reduced binding and
eﬃcacy, particularly against LRH-1. Given the improved solubi-
lity characteristic of 20a, c.f., the hydrocarbons 18, it is a useful
SF-1 selective compound. Compound 20b was LRH-1 selective
but with very poor eﬃcacy.
Finally, we examined some analogues with oxygen substitution
of the cyclopentane ring. The design was driven by the crystal
structure of compound 5 bound to LRH-1 described above, which
indicated a polar patch (Arg-393 and His-390) in the generally
hydrophobic ligand binding site (Figure 4).
We were delighted to ﬁnd that introduction of a 6-exo-hydroxy
substituent (24-exo) gave a substantial increase in both binding
and eﬃcacy against LRH-1 with more modest increases for SF-1.
The endo-epimer of 24 showed very similar binding and eﬃcacy
against both receptors as compound 18a lacking the oxygen
substitution. Examination of Figure 4 indicates that only the
exo alcohol is placed to interact with Arg-393 or His-390.
Acylation of the endo-alcohol (to give 25-endo) had little eﬀect
on binding to either receptor, although substantially reduced
eﬃcacy. Acylation of the exo-alcohol (to give 25-exo) substan-
tially reduced binding to SF-1 with little eﬀect on LRH-1,
although both showed greatly reduced eﬃcacy.
The 7-hydroxyl-substituted systems 29-exo and 29-endo showed
reduced binding as compared to the unsubstituted analogue 18a,
although eﬃcacies were reasonable. Acylation of the exo-alcohol
gave compound 30-exo, which was inactive against both LRH-1
and SF-1, indicating a size limitation of this part of the binding
pocket. Acylation of the endo alcohol to give 30-endo was well
tolerated.
Choice of Compounds as Biological Probes from the
Peptide Recruitment Assay. Compound 24-exo provides an
excellent replacement for compound 5 as a biological tool. It has
excellent stability, reasonable solubility in polar solvents, and
improved binding and efficacy against both LRH-1 and SF-1.
Little is lost in this FRET peptide recruitment assay by using the
1.6:1 mixture of 24-exo and 24-endo produced directly from the
zirconium-mediated reaction, thus avoiding a tricky separation.
Compounds 18o and 18p provide the most selective compounds
for SF-1, although the greater efficacy against SF-1, but still weak
binding and efficacy against LRH-1 favors 18j. The main
disadvantage of all of these is their very non-polar nature, which
may cause solubility problems in polar solvents, in which case
pyrrolidine 20a provides reasonable selectivity and may be pre-
ferred. Compound 18s was unique in providing LRH-1 selec-
tivity, although the activity was modest.
Direct Binding to Purified NR5A Receptors. Several com-
pounds were tested for direct binding using a native gel assay,
which generally maintains native protein structure and binding
activities.53 We purified both mSF-1 LBD complexed with dipa-
lmitoyl phosphatidyl-inositol (4,5) bisphosphate (PIP2) and
hLRH-1 LBD alone (no lipid added) to homogeneity as pre-
viously described,36 then added either dimethylsulfoxide (DMSO)
vehicle (0) or the indicated doses of 24-exo, 20a, 18j, or 18s
compounds (Figure 6). These binding reactions were allowed to
equilibrate for 16 h, separated by native polyacrylamide gel
electrophoresis (PAGE), and SF-1 protein was visualized with
Coomassie stain. The lower band in SF-1/PIP2 lanes is PIP2-
dependent, while the upper band represents SF-1 no longer
bound by phospholipid. Compound 24-exo clearly displaces the
bound PIP2 phospholipid from SF-1 almost completely at 1 μM,
and similarly, 20a can also displace PIP2 from SF-1, however,
with reduced potency and efficacy (Figure 6, left panel). Com-
pounds 18j and 18s do not appear competent to displace PIP2
from SF-1 LBD in this in vitro assay, even up to 100 μM.
Using hLRH-1 LBD alone that had not been complexed with
any phospholipids (Figure 6, right panel), we observed a clear
dose-dependent shift in hLRH-1 LBD native PAGE migration
upon 24-exo binding, although 20a was nearly as eﬃcacious
binding to LRH-1, a similar shift was only observed at 100 μM.
Compound 18j does not appear competent to shift hLRH-1 LBD
migration in native gels. Although not very eﬃcacious, 18s can
consistently shift hLRH-1 LBDmigration in this native gel assay,
albeit with reduced potency as compared to 24-exo.
Transcriptional Activation of Endogenous NR5A Target
Genes. Given this direct binding data, we then asked if 24-exo
was capable of regulating the SF-1-mediated transcription of an
endogenous target gene in living human cells. Human embryonic
kidney 293 (HEK293) cells stably expressing either empty vector
or SF-1 were treated with either DMSO vehicle or the indicated
doses of 24-exo for 24 h; each sample was subjected to real-time
quantitative polymerase chain reaction (RT-qPCR) to evaluate
the relative mRNA expression of the endogenous SF-1 target
Figure 6. Diﬀerential binding to NR5A receptors. Migration of puriﬁed
mouse SF-1 LBD complexed with PIP2 (SF-1/PIP2) or with human
LRH-1 LBD (LRH-1 alone) in native PAGE after incubation with
increasing amounts of indicated compounds. The faster migrating lower
band of SF-1 LBD without compound (0) is the SF-1/PIP2 complex.
Figure 7. Dose-dependent transcriptional activation of SF-1 by 24-exo
in living cells. Relative mRNA levels of SHP transcript are shown
in HEK293 cells stably expressing either empty vector (EV) or mouse
SF-1 (SF-1) following 24 h of treatment with the indicated dosage of 24-
exo (μM). Expression levels are shown relative to DMSO. *p < 0.05, and
***p < 0.001.
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gene SHP (Figure 7). Compound 24-exo induced a significant
dose-dependent increase in SHP transcripts beginning at 5 μM;
induction was dependent on the presence of SF-1 in these cells.
We next constructed a stable hLRH-1 HEK293 cell line in
addition to the SF-1 line and tested each compound for activation
of multiple endogenous target genes, which were previously
Figure 8. Diﬀerential transcriptional activation of endogenous NR5A targets in living cells. Relative mRNA expression of endogenous NR5A target
genes in HEK293 cells stably expressing either mSF-1 or hLRH-1. For each gene assessed, expression levels are shown relative to DMSO following 24 h
of treatment with indicated compound (10 μM). *p < 0.05, and **p < 0.01.
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identiﬁed using microarrays and gene proﬁling.54 SF-1 or LRH-1
cells were treated with 10 μM of indicated compounds for 24 h,
and the relative mRNA expression of each transcript was deter-
mined by RT-qPCR. SF-1 and LRH-1 protein levels were com-
parable in stably expressing cell lines, as determined by Western
blots (data not shown). We noted that cell viability and expres-
sion of housekeeping genes appeared unchanged following
treatment with compounds when compared to DMSO treatment.
Consistent with the phospholipid displacement assay, both
24-exo and 20a signiﬁcantly activate SF-1-mediated transcription
of the endogenous SHP, StAR, G0S2, and MeOX1 target genes,
while 18j and 18s do not (Figure 8, left panel). Also consistent
with the native gel assay, selective activation of all genes by LRH-
1 is observed in response to 10 μM 24-exo but not with similar
amounts of 18j and 18s (Figure 8, right panel). Interestingly, while
20a activated LRH-1 transcription of the StAR and G0S2 genes,
this compound failed to activate the SHP and MeOx1 genes,
suggesting that when bound to 20a, LRH-1's ability to recruit
needed cofactors at all genomic targets might be compromised.
Although 18j binds LRH-1 well, it exhibits poor eﬃcacy at these
particular target genes in the HEK293 cell line, raising the
possibility that a more relevant cellular or tissue context (such
as liver cells) might be required for 18j to fully activate LRH-1.
’CONCLUSION
A series of 1-alkoxy- and 1-alken-2-yl-substituted bicyclo-
[3.3.0]oct-2-enes and related bicycles were designed, synthe-
sized, and evaluated as agonists for the orphan NRs LRH-1 and
SF-1. The study achieved its main aims: a compound (in 24-exo,
RJW100) with similar activity to the best of our previous agonists
but with excellent stability; several compounds including 18j
(RJW102) and 20a (RJW103) with selectivity for SF-1, although
the former was inactive in in vivo studies, probably due to very
poor solubility in aqueous media; and a compound 18s (RJW101)
selective for LRH-1, although further work to improve potency is
needed. The precision and consistency of the SARs are notable
and probably due to the rigid bicyclic core used for all of the
compounds. Our preliminary cell-based studies have demon-
strated that the 24-exo is a consistently active agonist of SF-1 and
LRH-1 target gene expression in a variety of cell lines. While the
toxicity of 24-exo in animals remains to remains to be deter-
mined, we are currently assessing its utility in more complex
in vivo biological model systems such as in Caenorhabditis elegans
and zebraﬁsh, both of which express NR5A receptors. Further-
more, we expect that 24-exo will be a useful chemical tool to
probe the in vivo biological eﬀects of SF-1 and LRH-1 in mam-
malian systems. For instance, we speculate that 24-exo might
eventually replace the need to virally introduce Oct-4 in an iPS
assay and would thus provide one step toward achieving chemical
reprogramming.
’EXPERIMENTAL SECTION
Chemistry. General. NMR spectra were recorded on Bruker
AM300 or DPX400 spectrometers in CDCl3 or C6D6 and referenced
to residual protonated solvent (1H NMR) or the center peak of the
deuterated solvent triplet (13C NMR). Chemical shifts are reported in
parts per million downfield of TMS, and the following abbreviations
were used to denote coupling patterns: s, singlet; d, doublet; t, triplet; q,
quartet; m, multiplet (uninterpretable or unresolved); and fs, fine
splitting (resolved but unassigned small couplings). 13C NMR spectra
were proton decoupled and are reported as C, CH, CH2, and CH3,
depending on the number of directly attached protons, this being
determined by DEPT experiments. Assignments in NMR are only given
where not easily derived from the 1D data, and systematic numbering is
used. Protons described as H-a and H-b are on the endo and exo faces of
the bicyclic molecules, respectively. High-resolution mass spectra (HRMS)
were recorded on a VG Analytical 70-250-SE double focusing mass
spectrometer using electron impact ionization (EI) (at 70 eV) or on a
Bruker Apex III spectrometer using positive ion electrospray ionization.
Low-resolution mass spectra (LRMS) were recorded on a VGAnalytical
70-250-SE double focusing mass spectrometer (EI), a ThermoQuest
TraceMS gas chromatography mass spectrometry (GCMS) [EI and CI
(with ammonia as the reagent gas)], or on a VG platform quadrupole
spectrometer using positive ion electrospray ionization (ESIþ). Values
of m/z are reported in atomic mass units (a.m.u.) followed in parenth-
eses by the peak intensity (relative to the base peak of 100%). IR spectra
were obtained for all compounds but are not included. All compounds
were >95% pure by gas chromatography performed on a Hewlett-
Packard HP 6890 series GC system, using a HP-5 30 m column, with a
film thickness of 0.25 μm and 0.32mm internal diameter. The carrier gas
was helium, and the flow rate was 2.7 mL min-1 using 100:1 split
injection and an 80-275 at 25 C/min (held at 275 C for 4 min)
temperature program with a flame ionization detector.
All organometallic reactions were carried out with dry glassware
under an argon atmosphere using standard Schlenk and syringe techni-
ques. Merck silica gel 60 (0.040-0.063 mm) was used for puriﬁcation.
Unless given below, all materials were obtained from commercial
sources and, if necessary, dried and distilled before use. Petrol refers to
the fraction of petroleum ether that boils between 40 and 60 C and was
distilled before use. Tetrahydrofuran (THF) and diethylether used in
reactions were freshly distilled from sodium/benzophenone. n-Butyl-
lithium (nBuLi) was used as a 2.5 M solution in hexanes (Aldrich) and
was stored at 4 C.
Compounds 18b,h,k,m,o,r, 19, and 20b are reported elsewhere.44
The synthesis of the enyne starting materials, 1-ethyl-4-(hept-6-en-1-yn-
1-yl)benzene, N-methyl-N-(phenylprop-2-ynyl)prop-2-en-1-amine, tert-
butyldimethyl((7-phenylhept-1-en-6-yn-3-yl)oxy)silane 22, and tert-
butyldimethyl((7-phenylhept-1-en-6-yn-4-yl)oxy)silane 27 as well as
compounds 12a,c-j, 18c-g,i,l,n,p,q,t-w, 25, 29, and 30 are given in
the Supporting Information.
rac-(1S,5R)-1-Ethoxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene
(12b). To a stirred solution of rac-(3S,5R)-3-hexyl-2-phenyl-bicyclo-
[3.3.0]oct-1-en-3-ol39 (11) (142 mg, 0.50 mmol) in dry THF (4 mL) at
room temperature was added EtOH (0.29 mL, 5.0 mmol) followed by
addition of a solution of (þ)-camphorsulfonic acid (11.6 mg, 0.050 mmol)
in dry THF (1 mL). The stirring was continued at the same temperature
for 3.5 h after which the reaction mixture was poured onto saturated
aqueous solution of NaHCO3 (100 mL), and the products were extracted
with Et2O (3  75 mL). The combined organic phases were washed
with H2O (3  100 mL) and brine (100 mL). Drying over anhydrous
MgSO4 and filtration followed by concentration in vacuo and purifica-
tion of the crude material by column chromatography on Al2O3 (basic,
grade III) with 2.5% Et2O in petrol as the eluent gave the title compound
as a yellow oil (0.108 g, 69%). 1H NMR (400 MHz, CDCl3): δ 7.27-
7.13 (5H, m), 3.40 (1H, m), 3.26 (1H,m), 2.65 (1H, dd, J = 17.1, 8.3 Hz,
H-4b), 2.45-2.37 (1H, m, H-5), 2.14-2.08 (2H, m), 2.06-1.93
(2H, m), 1.66-1.49 (3H,m), 1.44-1.29 (3H,m), 1.24-1.10 (10H, m),
0.77 (3H, t, J = 6.8 Hz, CH3).
13CNMR (100.5 MHz, CDCl3): δ 145.51
(C), 137.28 (C), 136.09 (C), 129.21 (CH), 128.10 (CH), 126.59 (CH),
103.39 (C), 58.40 (CH2), 42.99 (CH), 42.15 (CH2), 37.89 (CH2),
35.83 (CH2), 31.81 (CH2), 29.91 (CH2), 29.43 (CH2), 28.25 (CH2),
25.40 (CH2), 22.77 (CH2), 15.98 (CH3), 14.21 (CH3). LRMS (EI)m/z
= 312 ([M]þ, 93%), 283 (100%), 195 (59%). HRMS (EI) found, [M]þ,
312.2458. C22H32O requires, 312.2453.
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General Procedure. To a solution of Cp2ZrCl2 (0.293 g, 1.0 mmol)
in dry THF (5 mL) cooled to -78 C was added nBuLi (0.80 mL of a
2.5 M solution in hexanes, 2.0 mmol) dropwise (over ∼2 min). After
25 min, a solution of the appropriate enyne (1.0 mmol) in dry THF
(3 mL) was added dropwise. After 30 min at -78 C, the reaction
mixture was allowed to warm to room temperature and continued to stir
for 2-3 h. After the reaction mixture was recooled to-78 C, a solution
of the appropriate 1,1-dihalo alkane (1.1 mmol) in dry THF (1 mL) was
added followed by dropwise addition of LDA (0.64 mL of a 1.8 M
solution, 1.15 mmol). The reaction mixture was stirred at -78 C for
15 min before dropwise addition of the corresponding lithium acetylide.
[Lithium acetylide was freshly prepared from alkyne (3.0 mmol) in dry
THF (3 mL) and nBuLi (1.2 mL of a 2.5 M solution in hexanes,
3.0 mmol) at-5 C over 15 min]. The stirring was continued for 0.5-1
h during which the reaction mixture was allowed to warm to -55 C
before addition of MeOH (10 mL) and saturated aqueous solution of
NaHCO3 (10 mL). The whole mixture was allowed to warm to room
temperature and left stirring for 12-16 h. The mixture then was poured
onto H2O (100 mL), and the products were extracted with Et2O (3 
75 mL). The combined organic phases were washed with H2O (3 
100 mL) and brine (100 mL). Drying over anhydrous MgSO4 and
filtration followed by concentration in vacuo gave the crude products
mostly as yellow oils.
rac-(1R,5R)-3-Hexyl-2-phenyl-1-(1-phenylvinyl)-bicyclo[3.3.0]oc-
t-2-ene (18a). General procedure was used with 1-(hept-6-en-1-
ynyl)benzene, 1,1-dibromoheptane, and 1-ethynylbenzene as compo-
nents. Purification of the crude material by column chromatography on
SiO2 (230-400 mesh) with hexanes as the eluent gave the title com-
pound as a pale yellow oil (0.318 g, 86%). 1HNMR (300MHz, CDCl3):
δ 7.35-7.24 (10H, m), 5.04 (1H, d, J = 1.6 Hz, CdCH2), 5.02 (1H, d,
J = 1.6 Hz, CdCH2), 2.43 (1H, tdd, J = 8.6, 3.2, 1.4 Hz, H-5), 2.34 (1H,
fs ddd, J = 16.2, 8.4, 1.0 Hz, H-4b), 2.12-1.97 (3H, m), 1.85 (1H, dtd,
J = 12.2, 9.7, 6.8Hz), 1.68 (2H, m), 1.62-1.52 (3H,m), 1.43-1.21 (8H,
m), 0.88 (3H, t, J = 6.8 Hz, CH3).
13C NMR (75 MHz, CDCl3):
δ 155.39 (CdCH2), 144.40 (C), 142.48 (C), 138.95 (C), 137.98 (C),
129.69 (2CH), 127.93 (2CH), 127.55 (2CH), 127.52 (2CH), 126.47
(CH), 126.33 (CH), 114.45 (CdCH2), 70.16 (C-1), 45.71 (CH-5),
43.83 (CH2), 36.33 (CH2), 35.64 (CH2), 31.70 (CH2), 29.89 (CH2),
29.41 (CH2), 27.87 (CH2), 25.60 (CH2), 22.60 (CH2), 14.06 (CH3).
LRMS (EI) m/z: 370 ([M]þ 3 , 100%), 299 (35%), 267 (85%). HRMS
(EI) found, [M]þ, 370.2655. C26H34 requires, 370.2661.
rac-(1R,5R)-1-(Hex-1-en-2-yl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-
2-ene (18j). General procedure was used with 1-(hept-6-en-1-
ynyl)benzene, 1,1-dibromoheptane, and 1-hexyne as components. Pur-
ification of the crude material by column chromatography on SiO2
(230-400 mesh) with hexanes as the eluent gave the title compound as
a pale yellow oil (0.263 g, 75%). 1H NMR (300 MHz, CDCl3): δ 7.29-
7.17 (3H, m), 7.06-7.02 (2H, m), 4.81 (1H, q, J = 1.4 Hz, CdCH2),
4.79 (1H, q, J = 1.4 Hz, CdCH2), 2.84 (1H, fs dd, J = 16.8, 8.4 Hz, H-
4b), 2.43 (1H, dddd, J = 9.7, 8.4, 3.2, 1.6 Hz, H-5), 2.21-2.01 (5H, m),
1.88 (1H, dtd, J = 12.0, 9.4, 7.0 Hz, H-6), 1.70 (1H, m), 1.60-1.48
(6H, m), 1.45-1.33 (4H, m), 1.30-1.21 (6H, m), 0.95 (3H, t, J = 7.2
Hz, CH3), 0.86 (3H, t, J = 6.9 Hz, CH3).
13C NMR (75 MHz, CDCl3):
δ 154.57 (CdCH2), 141.21 (C), 139.63 (C), 138.04 (C), 129.40
(2CH), 127.42 (2CH), 126.11 (CH), 107.27 (CdCH2), 71.24 (C-
1), 45.53 (CH-5), 44.33 (CH2), 36.67 (CH2), 33.84 (CH2), 32.05
(CH2), 31.68 (CH2), 30.75 (CH2), 29.59 (CH2), 29.13 (CH2), 28.06
(CH2), 25.70 (CH2), 23.05 (CH2), 22.61 (CH2), 14.15 (CH3), 14.04
(CH3). LRMS (EI) m/z: 350 ([M]
þ 3 , 57%), 307 (26%), 293 (100%).
HRMS (EI) found, [M]þ, 350.2979. C26H38 requires, 350.2974.
r a c -(1R,5R)-3-Hexyl-1-(phenylvinyl)-2-(propan-3-ol)-bicyclo[3.-
3.0]oct-2-ene (18s). General procedure was used with tert-butyl(dec-
9-en-4-yn-1-yloxy)dimethylsilane, 1,1-dibromoheptane, and 1-ethynyl-
benzene as components with the exception that the reaction was carried
out on 2.0 mmol scale. Crude product from the three component
coupling was purified by flash column chromatography on silica, and
then, the TBDMS group was removed with TBAF [2.0 mL of a 1.0 M
solution in THF (2.0 mmol) in dry THF (8.0 mL) at room temperature
for 20 h]. Purification of the crude material by column chromatography
on SiO2 (230-400 mesh) with hexanes as the eluent gave the title
compound as a yellow oil (0.430 g, 61% over two steps). 1H NMR
(400 MHz, CDCl3): δ 7.24-7.16 (5H, m), 5.15 (1H, d, J =
1.8 Hz, C=CH2), 4.98 (1H, d, J = 1.8 Hz, CdCH2), 3.65 (2H, q, J =
6.5 Hz, CH2OH), 2.34 (1H, tt, J = 9.0, 2.0 Hz, H-5), 2.24 (1H, dd,
J = 16.0, 9.0 Hz, H-4b), 2.13-2.02 (4H, m), 1.87-1.61 (6H, m),
1.59-1.52 (1H, m), 1.48-1.38 (1H, m), 1.37-1.26 (10H, m), 0.91
(3H, t, J = 6.9 Hz, CH3).
13C NMR (100.5 MHz, CDCl3): δ 155.95
(CdCH2), 144.36 (C), 139.80 (C), 136.21 (C), 127.83 (2CH), 127.37
(2CH), 126.33 (CH), 113.26 (CdCH2), 70.38 (C-1), 63.62
(CH2OH), 43.99 (CH-5), 43.80 (CH2-4), 36.55 (CH2), 36.05
(CH2), 33.45 (CH2), 31.84 (CH2), 29.52 (CH2), 29.27 (CH2), 27.73
(CH2), 25.34 (CH2), 22.65 (CH2), 22.54 (CH2), 14.10 (CH3). LRMS
(CI) m/z: 353 ([M þ H]þ, 100%), 249 (37%). HRMS (EI) found,
[M]þ, 352.2767. C25H36O requires, 352.2766.
rac-(1S,5R)-3-Hexyl-2-phenyl-1-(phenylvinyl)-7-methylaza-bicy-
clo[3.3.0]oct-2-ene (20a). General procedure was used with N-
methyl-N-(phenylprop-2-ynyl)prop-2-en-1-amine, 1,1-dibromoheptane, and
1-ethynylbenzene as components. Purification of the crude material by
column chromatography on Al2O3 (basic, grade III) with 2.5% of Et2O
in hexanes as the eluent gave the title compound as a pale yellow oil
(0.240 g, 62%). 1H NMR (400 MHz, CDCl3): δ 7.38-7.25 (10H, m),
5.10 (1H, d, J = 1.1 Hz, CdCH2), 4.93 (1H, d, J = 1.1 Hz, CdCH2),
2.69 (1H, d, J = 9.4 Hz, H-8), 2.68 (1H, dd, J = 8.4, 4.0 Hz, H-6), 2.63
(1H, d, J = 9.4 Hz, H-8), 2.63 (1H, tdd, J = 7.9, 4.0, 2.0 H-5), 2.50
(1H, fs dd, J = 16.8, 8.8, Hz, H-4b), 2.45 (1H, dd, J = 8.4, 4.0 Hz,
H-6), 2.31 (3H, s, N-CH3), 2.15 (1H, dd, J = 16.8, 1.7, Hz, H-4a),
2.12-2.08 (2H, m, C-3-CH2), 1.45-1.34 (2H, m), 1.32-1.22 (6H,
m,), 0.89 (3H, t, J = 7.0 Hz, CH3).
13C NMR (100.5 MHz, CDCl3):
δ 153.64 (CdCH2), 143.66 (C), 141.53 (C), 139.52 (C), 137.54 (C),
129.89 (2CH), 127.73 (2CH), 127.65 (2CH), 127.57 (2CH), 126.71
(CH), 126.46 (CH), 114.98 (CdCH2), 70.11 (C-1), 65.77 (2CH2-6
þ 8), 46.35 (CH-5), 42.73 (N-CH3), 41.98 (CH2-4), 31.67 (CH2),
29.81 (CH2), 29.39 (C-3-CH2), 27.72 (CH2), 22.58 (CH2), 14.06
(CH3). LRMS (ESI
þ) m/z: 386 ([M þ H]þ, 100%). HRMS (ESIþ)
found, [M þ H]þ, 386.2832. [C28H36N]þ requires, 386.2842.
rac-(1R,5R,6R)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-bic-
yclo[3.3.0]oct-2-ene (24-exo) and rac-(1R,5R,6S)-3-Hexyl-6-hydro-
xy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene (24-endo). To
a solution of Cp2ZrCl2 (1.465 g, 5.0 mmol) in dry THF (25mL) cooled
to -78 C was added nBuLi (4.0 mL of a 2.5 M solution in hexanes,
10.0 mmol) dropwise. After 20 min, a solution of tert-butyl-
dimethyl((7-phenylhept-1-en-6-yn-3-yl)oxy)silane (1.50 g, 5.0 mmol)
in dry THF (15 mL) was added dropwise. After 30 min at-78 C, the
reaction mixture was allowed to warm to room temperature and con-
tinued to stir for 3 h. After the reaction mixture was recooled to -
78 C, a solution of 1,1-dibromoheptane (1.42 g, 5.5 mmol) in dry
THF (5 mL) was added followed by dropwise addition of LDA
(3.06 mL of a 1.8 M solution, 5.5 mmol). The reaction mixture was
stirred at -78 C for 15 min before dropwise addition of lithium
phenylacetylide solution [freshly prepared from phenylacetylene
(1.65 mL, 15.0 mmol) in dry THF (15 mL) and nBuLi (6.0 mL of a
2.5 M solution in hexanes, 15.0 mmol) at -10 C over 15 min]. The
stirring was continued for 45 min during which the reaction mixture
was allowed to warm to-55 C before addition ofMeOH (30mL) and
saturated aqueous solution of NaHCO3 (30 mL). The mixture
was allowed to warm to room temperature and left stirring for 5 h
before pouring onto H2O (200 mL) and extracting the products into
Et2O (3  200 mL). The combined organic phases were washed with
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H2O (3  300 mL) and brine (300 mL). Drying over anhydrous
MgSO4 and filtration followed by concentration in vacuo gave the
crude product as a yellow oil. Purification by flash chromatography on
SiO2 with 2.5% of Et2O in hexanes furnished the TBDMS protected
alcohols 23 (1.6:1 exo:endo) as a yellow oil (2.20 g, 88%).
The TBDMS-protected alcohols 23 (2.20 g, 4.40 mmol) were
dissolved in dry THF (44 mL) followed by addition of TBAF (17.60
of 1.0 M solution in THF), and the reaction mixture was stirred at room
temperature for 20 h. Then, the mixture was poured onto H2O
(200 mL) and extracted with Et2O (2  150 mL). The organic phases
were washed withH2O (3 200mL) and brine (1 200mL) and dried
over MgSO4. Concentration in vacuo, followed by separation by column
chromatography on Al2O3 (basic, grade III) and 2.5% EtOAc in hexanes
as the eluent gave the partly separated isomers: 0.277 g of pure 24-endo
(14%), 0.650 g of mixed fractions (33%), and 0.556 g of pure 24-exo
(29%), for a combined yield of 1.483 g (76%). Further chromatography
of the mixed fractions allowed additional pure 24-exo and 24-endo to be
isolated. Compound 24-exo: 1HNMR (300MHz, CDCl3):δ 7.37-7.19
(10H, m), 5.08 (1H, d, J = 1.5 Hz, CdCH2), 5.00 (1H, d, J = 1.5 Hz,
CdCH2), 3.96 (1H, br s, H-6), 2.39 (1H, fs dd, J = 16.2, 9.6 Hz, H-
4b), 2.30 (1H, fs d, J = 9.6 Hz, H-5), 2.15-2.0 (4H, m), 1.79-1.67
(3H, m), 1.38-1.20 (9H, m), 0.87 (3H, t, J = 6.8 Hz, CH3). 13C NMR
(75MHz, CDCl3): δ 154.69 (CdCH2), 144.21 (C), 141.19 (C), 139.17
(C), 137.43 (C), 129.73 (2CH), 127.78 (2CH), 127.72 (2CH), 127.62
(2CH), 126.66 (CH), 126.59 (CH), 114.99 (CdCH2), 82.10 (CH-6),
69.40 (C-1), 55.92 (CH-5), 40.29 (CH2), 34.04 (CH2), 32.13 (CH2),
31.66 (CH2), 29.73 (CH2), 29.37 (CH2), 27.83 (CH2), 22.58 (CH2),
14.06 (CH3). LRMS (EI) m/z: 386 ([M]
þ•, 36%), 283 (21%), 283
(100%). HRMS (EI) found, [M]þ, 386.2611. C28H34O requires,
386.2610. Compound 24-endo: 1H NMR (300 MHz, CDCl3): δ 7.35-
7.21 (10H, m), 5.075 (1H, d, J = 1.5 Hz, CdCH2), 4.96 (1H, d, J = 1.5
Hz, CdCH2), 4.19 (1H, ddd, J = 9.1, 8.5, 5.5 Hz, H-6), 2.63 (1H, fs dd,
J = 17.2, 2.1 Hz, H-4a), 2.50 (1H, fs td, J = 8.5, 2.1 Hz, H-5), 2.17-
2.01 (3H, m), 1.86 (1H, ddt, J = 10.4, 5.5, 4.4 Hz, H-7b), 1.74-1.70
(2H, m), 1.57 (1H, ddd, J = 10.4, 9.1, 8.1 Hz, H-7a), 1.50-1.35 (2H, m),
1.29-1.24 (7H, m), 0.87 (3H, t, J = 6.8 Hz, CH3). 13C NMR (75 MHz,
CDCl3): δ 154.86 (CdCH2), 144.00 (C), 143.28 (C), 139.37 (C),
137.06 (C), 129.82 (2CH), 127.78 (2CH), 127.70 (2CH), 127.61
(2CH), 126.70 (CH), 126.56 (CH), 114.88 (CdCH2), 74.55 (CH-
6), 68.83 (C-1), 49.19 (CH-5), 33.77 (CH2), 33.49 (CH2), 31.83
(CH2), 31.66 (CH2), 29.89 (CH2), 29.47 (CH2), 27.93 (CH2), 22.60
(CH2), 14.06 (CH3). LRMS (EI)m/z: 386 ([M]
þ•, 12%), 368 (17%), 283
(69%). HRMS (EI) found, [M]þ, 386.2600. C28H34O requires, 386.2610.
Biology Experimental. Transcriptional Assays. Stable cell lines
expressing either N-terminal 3XFlag-tagged mouse SF-1 or human
LRH-1 were generated with the T-Rex Flip-In system in the HEK293
T-Rex cell line (Invitrogen). Expression and tetracycline (Tet) induci-
bility were verified by Western blot analysis using an anti-3XFlag M2
monoclonal antibody (Sigma). For all transcriptional assays, com-
pounds dissolved in DMSO were added for 16 h after initial addition
of 100 ng/mLTet or EtOH vehicle control. Low levels of transduced SF-
1 and LRH-1 were observed in cell lines before the addition of Tet, most
likely due to stochastic “leakiness” of the TET-transcriptional repressor,
as often observed. Messenger RNA transcript abundance relative to the
cyclophilin housekeeping gene is shown, with DMSO control set equal
to 1. All transcripts were analyzed by quantitative PCR using the
following sets of validated primers:
hCyclophilinf TTTCATCTGCACTGCCAAGA
hCyclophilinr TTGCCAAACACCACATGCT
hSHPf GCTTAGCCCCAAGGAATATGC
hSHPr TTGGAGGCCTGGCACATC
hStARf CCCATGGAGAGGCTCTATGAA
hStARr GTTCCACTCCCCCATTGCT
hMEOX1f GGCGGAGAAAGGAGAGTTCA
hMEOX1r TCCTTGCGGGCTTTGCT
hG0S2f CAGAGAAACCGCTGACATCTAGAA
hG0S2r CAGCAAAACTCAATCCCAAACTC
Protein Purification and PI(4,5)P2 Displacement.Details of the SF-1
LBD construct, purification, and PI(4,5)P2 exchange have been pre-
viously described.35b,36 For compound displacement assays, 2.0 μL of
serially diluted compounds in DMSO were dosed into 48.0 μL of
crystallography pure 1.0 μM mSF-1 LBD/PI(4,5)P2 complexes, in
20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
(8.0) and 5 mM MgCl2, for 2 h at 37 C. This entire reaction was then
separated by native PAGE on precast 4-16% gradient Bis/Tris-buffered
gels (Invitrogen), which maintains SF-1LBD/PI(4,5,)P2 association.
Gels were then stained with Coomassie brilliant blue to visualize
compound-induced changes in the native gel migration pattern of SF-
1 LBD/PI(4,5)P2.
Crystallogaphy. Purification of human LRH-1 is as described previ-
ously.35b Endogenous phospholipids were replaced with GR8470
(compound 5) using liposome-mediated exchange as described35b with
the exception that liposomes were composed of 1,2-ditetracosanoyl-sn-
glycero-3-phosphocholine (PC24) (Avanti Polar Lipids). Briefly, GR8470
inDMSOwas added to PC24 in water to a final concentration of 0.8mM
and was mixed with an equal volume of 8 mg/mL LRH-1, giving a final
ligand:protein ratio of 3. Exchange wasmonitored by purifying the LRH-
1/ligand complex on a PD10 size exclusion column and determining the
complex molecular weight by mass spectroscopy as described.35b By this
method, exchange did not improve beyond 5 days. Purified LRH-1 was
then mixed with TIF2 peptide in a 1:2 molar ratio and concentrated to
6-8 mg/mL for crystallization trials.
Crystals of the complex were obtained in 0.2 M ammonium sulfate,
0.1 M sodium acetate trihydrate, pH 4.6, and 25% w/v polyethylene
glycol 4000 and were quickly dunked into the same buﬀer with 12%
glycerol and 12% ethylene glycol prior to freezing in liquid nitrogen.
Data were collected at beamline 17ID (IMCACAT) at the Advanced
Photon Source at Argonne National Laboratories using an ADSCQ210.
Images were integrated and scaled using HKL2000. The complex
crystallized in the space group P21 with unit cell constants of A =
52.7, B = 89.0, C = 65.4, and β = 101.7, with two complexes per
asymmetric unit. The structure was solved by molecular replacement
using the apo LRH-1 structure (1YOK) as a search model. The model
was reﬁned against 1.75 Å data using Refmac555 and rebuilt using
Coot.56 The model was reﬁned to a ﬁnal R = 18.7 and Rfree = 21.4 and
contained two copies of LRH-1 LBD, two copies of TIF2 peptide, two
copies GR8470, one glycerol molecule, three ethylene glycol molecules,
and 305 water molecules. The bond length and angle root-mean-square
deviation from ideality are 0.007 Å and 1.098, respectively.
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